93 results on '"Haarman, E"'
Search Results
2. 178 Toward targeted exhaled breath analysis for young children in cystic fibrosis care to detect bacteria in the lungs
3. Otologic features in patients with Primary Ciliary Dyskinesia- an EPIC-PCD study
4. Primary ciliary dyskinesia in Volendam: diagnostic and phenotypic features in patients with a CCDC114 mutation
5. Sinonasal features in patients with Primary Ciliary Dyskinesia - an EPIC-PCD study
6. Modulation of Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia; Preliminary Results
7. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
8. An international survey on nasal nitric oxide measurement practices for the diagnosis of primary ciliary dyskinesia
9. Resistance Testing and Mechanisms of Resistance in Childhood Leukemia : Studies from Amsterdam
10. BCL-2 Expression in Childhood Leukemia Versus Spontaneous Apoptosis, Drug Induced Apoptosis, and in vitro Drug Resistance
11. 563: Real-life initiation of elexacaftor/ivacaftor/tezacaftor in cystic fibrosis patients with severe lung disease
12. Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
13. International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives.
14. Quality of life and psychosocial outcomes in children with severe acute asthma and their parents
15. The Controversies and Difficulties of Diagnosing Primary Ciliary Dyskinesia
16. P208 Anxiety, depression and resilience during COVID-19 in Dutch patients with cystic fibrosis or primary ciliary dyskinesia and their caregivers
17. Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia
18. EFFICACY AND SAFETY BY AGE GROUP FROM THE PHASE III STUDIES OF BRONCHITOL (INHALED MANNITOL) IN PATIENTS WITH CF: 236
19. Topological Data Analysis Coupled with Machine Learning Reveals New Genotype-Phenotype Relationships in Primary Ciliary Dyskinesia
20. Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials.
21. BCL-2 Expression in Childhood Leukemia Versus Spontaneous Apoptosis, Drug Induced Apoptosis, and in vitro Drug Resistance
22. Resistance Testing and Mechanisms of Resistance in Childhood Leukemia
23. Higher health care consumption associated with ethnicity in children with asthma
24. P416 Improving treatment adherence in adolescents with cystic fibrosis: feasibility of the “CF My Way” intervention program
25. Kinderlongziekten VUmc
26. P047 Detection of Pseudomonas aeruginosa in exhaled breath of cystic fibrosis patients
27. Astma en het beperken van astma-exacerbaties
28. Prevalence of rhinoviruses in young children of an unselected birth cohort from the Netherlands
29. Prevalence of rhinoviruses in young children of an unselected birth cohort from the Netherlands
30. Primary ciliary dyskinesia: From diagnosis to molecular mechanisms
31. WS03.3 A phase II, randomised, double-blind, placebo-controlled, crossover study of dry powder mannitol in children with cystic fibrosis (CF)
32. Virus Dependent Changes In Exhaled Molecular Profile In Wheezy Infants. Prospective Data From The EUROPA Study
33. 77* Phase III Study [CF-302] of inhaled dry powder mannitol (Bronchitol(tm)) in cystic fibrosis – results from the 6 month open label phase
34. 78 Combined data from two phase III studies of Bronchitol (inhaled dry powder mannitol) in adult cystic fibrosis (CF) patients
35. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children
36. Astma en beperken van astma-exacerbaties.
37. Clinical relevance of drug resistance in childhood leukemia
38. Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome.
39. Lung function from school age to adulthood in primary ciliary dyskinesia
40. The volatile metabolome and microbiome in pulmonary and gastro-intestinal disease
41. The Non-Invasive Detection of Pulmonary Exacerbations in Disorders of Mucociliary Clearance with Breath Analysis: A Systematic Review.
42. Clinical efficacy and satisfaction of a digital wheeze detector in a multicentre randomised controlled trial: the WheezeScan study.
43. Depression, anxiety, and resilience during COVID-19 in Dutch patients with cystic fibrosis or primary ciliary dyskinesia and their caregivers.
44. Axonemal structures reveal mechanoregulatory and disease mechanisms.
45. Nasal nitric oxide measurement in children for the diagnosis of primary ciliary dyskinesia: European Respiratory Society technical standard.
46. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study.
47. An international survey on nasal nitric oxide measurement practices for the diagnosis of primary ciliary dyskinesia.
48. Prediction of asthma in early preschool wheezing by electronic nose analysis.
49. Anxiety and depression in Dutch patients with primary ciliary dyskinesia and their caregivers: associations with health-related quality of life.
50. International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.